ALP-Bio AG Secures €1.9 Million to Innovate Biologics Development
Based in Schlieren, ALP-Bio AG has announced a significant milestone in its journey to revolutionize biologics development. The Swiss biotech startup has successfully raised €1.9 million in pre-seed funding. This capital will bolster the advancement of their pioneering platform that merges human immune organoid biology with generative AI, aiming to aid antibody developers in identifying, understanding, and mitigating immunogenicity risks earlier in the drug development process.
Funding Details and Strategic Vision
The funding round was predominantly led by Munich-based venture capital firm 42CAP, with additional participation from Venture Kick and a network of strategic angel investors. This financial boost is set to enhance ALP-Bio’s experimental and computational capabilities, thereby accelerating its mission to transform antibody development from a reactive to a proactive discipline.
Dr. Christian Vahlensieck, CEO of ALP-Bio AG, articulated the industry’s challenge, stating, “Immunogenicity is one of the largest hidden costs in biologics, and the industry has for too long accepted late surprises as the norm. We believe this risk should be measured and reduced years earlier than today.”
European Market Context and ALP-Bio’s Unique Position
ALP-Bio’s pre-seed round is part of a broader 2026 EU startup funding model that emphasizes AI-driven drug discovery, human-relevant preclinical biology, biologics infrastructure, and pharmaceutical R&D data systems. Notable Swiss benchmarks include Zürich-based Rivia’s €13 million Series A for clinical trial data infrastructure and Geneva-based FluoSphera’s €1.23 million for drug discovery tools, highlighting a domestic shift towards biotech infrastructure.
Across Europe, companies like Helical, Sable Bio, Ternary Therapeutics, and others have attracted investment, showing a clear trend towards platforms that prioritize early-stage, data-rich, and experimentation-driven drug development. In this context, ALP-Bio’s approach of combining immune organoid readouts with generative AI places it in a unique position to contribute to early risk reduction for biologics and antibody development, diverging from traditional downstream clinical execution models.
Scientific Approach and Platform Development
ALP-Bio’s scientific philosophy is rooted in the belief that immunogenicity challenges cannot be addressed by computation alone. Dr. Lucas Schaus, CSO of ALP-Bio AG, explains, “Our scientific belief is that immunogenicity cannot be solved by computation alone. By combining readouts from human immune organoids with AI, we can generate the kind of biofeedback needed to make antibody design more informed, iterative, and ultimately more useful for discovery and optimization teams.”
The company’s platform leverages human tonsil organoid technology, which simulates relevant immune activity in vitro, alongside AI models that process and learn from comprehensive biological data sets. This integration aims to enhance lead candidate screening, ADA risk stratification, and sequence optimization while maintaining therapeutic efficacy.
Future Directions and Collaborative Opportunities
The pre-seed funding will be strategically allocated to expand ALP-Bio’s experimental immune organoid capabilities, increase automation and throughput, and initiate partnership projects targeting the immunogenicity risks of primary antibody candidates. Additionally, the company plans to develop its scientific and commercial presence in Switzerland and the United States.
ALP-Bio is now actively engaging with pharmaceutical and biotechnology partners interested in early-access immunogenicity collaborations. The focus is on antibody programs where early risk mitigation can enhance candidate selection, reduce downstream uncertainty, and support informed development decisions.
For more information, visit the source link: Here
“`
